8-K: Climb Bio Sues Alumis Over Budoprutug Milestone Payment

Climb Bio, Inc. has filed a lawsuit against Alumis Inc. and its subsidiary Acelyrin, Inc. seeking a declaratory judgment that it does not owe a $3 million milestone payment related to its budoprutug drug candidate.

Summary

• Climb Bio, Inc. filed a complaint in Delaware Superior Court against Alumis Inc. and its wholly owned subsidiary, Acelyrin, Inc., on December 31, 2025.
• The lawsuit concerns a dispute over an Asset Purchase Agreement (APA) dated January 11, 2024, for the acquisition of certain assets related to budoprutug, a clinical-stage anti-CD19 monoclonal antibody.
• Climb Bio seeks a declaratory judgment that its budoprutug drug candidate is not a 'Product' as defined in the APA, and therefore, it does not owe a $3 million milestone payment demanded by Alumis.
• The APA defines a 'Product' as limited to a budoprutug drug that would infringe 'Royalty-Bearing Patents,' which are further defined as patents included in the transferred assets or filed within nine months of the APA's closing date.
• Climb Bio asserts that no 'Royalty-Bearing Patents' exist, as none were transferred by Acelyrin, nor were any filed within the nine-month period, meaning no 'Product' under the APA can be developed.
• Alumis's interpretation of the APA could lead to payments upwards of $100 million beyond the initial asset purchase price, despite Alumis not contributing any patents to establish exclusivity for Climb Bio's drug candidate.
• Climb Bio successfully dosed its first patient with budoprutug in a Phase 2 clinical trial on November 17, 2025, and subsequently received an invoice from Alumis for a $3 million milestone payment due January 1, 2026.
• Climb Bio acquired Tenet Medicines, Inc., the original buyer of the budoprutug assets, in June 2024.
• Climb Bio faced significant unexpected work and costs to make budoprutug clinically viable due to issues with materials transferred by Acelyrin, including one lot of clinical supply being unusable.

Sentiment

Score: 3

Explanation: The filing details a significant legal dispute over a $3 million payment and potentially over $100 million in future liabilities, stemming from an asset purchase agreement. While Climb Bio is progressing its clinical trial, the legal challenge and unexpected development costs represent substantial negative financial and operational headwinds, creating significant uncertainty for investors.

Positives

• Climb Bio successfully dosed its first patient with budoprutug in a Phase 2 clinical trial on November 17, 2025, demonstrating progress in its development program for immune-mediated diseases.
• The company is actively developing budoprutug, a clinical-stage anti-CD19 monoclonal antibody, with a mission to deliver high-impact, disease-modifying medicines.

Negatives

• Climb Bio is engaged in a legal dispute with Alumis Inc. and Acelyrin, Inc. over a $3 million milestone payment, which Alumis demands by January 1, 2026.
• Alumis's interpretation of the Asset Purchase Agreement could result in over $100 million in future payments to Alumis, which Climb Bio disputes as unwarranted given the lack of 'Royalty-Bearing Patents'.
• Climb Bio incurred significant unexpected costs and performed additional work to render budoprutug clinically viable due to issues with materials transferred by Acelyrin, including one lot of designated clinical supply being unusable.
• Acelyrin had previously terminated development of budoprutug and its clinical trial without drafting a clinical study report prior to the asset sale to Tenet Medicines, Inc.

Risks

• Financial risk of owing a $3 million milestone payment to Alumis Inc. by January 1, 2026, if the court rules against Climb Bio.
• Potential for significant future milestone and royalty payments (upwards of $100 million) to Alumis if the court determines Climb Bio's budoprutug is a 'Product' under the APA.
• Litigation costs and potential negative impact on company resources and management focus due to the ongoing legal dispute.
• Reputational risk associated with a public legal dispute with a former asset seller in the biopharmaceutical industry.

Future Outlook

Climb Bio seeks court intervention to clarify its obligations under the Asset Purchase Agreement, aiming for a declaratory judgment that it does not owe the $3 million milestone payment and is not subject to future payment obligations for its budoprutug drug candidate. The outcome of this litigation will significantly determine the financial liabilities related to the budoprutug program and could impact the company's long-term financial planning.

Management Comments

• "Climb seeks the Courts intervention to resolve a dispute between the parties concerning their January 11, 2024 Asset Purchase Agreement."
• "Climb is not (and could not be) developing a Product, and does not owe any obligations under the APA in connection with its development or commercialization of budoprutug."
• "Climb has repeatedly attempted to better understand Alumis position and resolve this dispute out of court, but Alumis has rebuffed all attempts to achieve an amicable resolution."
• "Climb denies that any such payment is owed under the clear and unambiguous terms of the APA, which limit this milestone payment to a Product."
• "Defendants have no right to further profit from Climbs significant independent work to develop budoprutug when Defendants failed to provide any Royalty-Bearing Patents."

Industry Context

This filing highlights a common challenge in the biopharmaceutical industry: disputes over intellectual property rights and milestone payments in asset purchase agreements, particularly when patent ownership and definitions of 'product' are ambiguous or contested. Such disputes can arise from complex licensing structures and changes in corporate ownership, impacting development timelines and financial forecasts for clinical-stage assets. The outcome of this case could set precedents for how 'Royalty-Bearing Patents' and 'Product' definitions are interpreted in future biotech M&A and licensing deals.

Comparison to Industry Standards

• The dispute over the definition of 'Royalty-Bearing Patents' and 'Product' is a critical aspect of intellectual property licensing and asset acquisition in biotech. Industry standard Asset Purchase Agreements (APAs) typically define these terms with precision to avoid such ambiguities, suggesting a potential weakness in the original APA's drafting or interpretation.
• The situation where a seller (Acelyrin/Alumis) seeks significant earn-out payments without contributing active, enforceable patent protection for the acquired asset (budoprutug) is unusual and contrary to the typical risk-reward balance in biotech deals, where patent exclusivity is a primary driver of value and justification for such payments.
• Climb Bio's need to incur significant unexpected costs to make budoprutug clinically viable, despite an upfront payment of over $7 million, suggests a potential failure in due diligence or misrepresentation of the asset's development stage by the seller, which is a known risk factor in early-stage asset acquisitions within the industry.

Legal Proceedings

• Climb Bio, Inc. filed a complaint in Delaware Superior Court against Alumis Inc. and Acelyrin, Inc. on December 31, 2025.
• The lawsuit seeks a declaratory judgment that Climb Bio's budoprutug drug candidate is not a 'Product' under the Asset Purchase Agreement (APA) dated January 11, 2024.
• Climb Bio contends it does not owe a $3 million milestone payment demanded by Alumis, due January 1, 2026, for initiating a Phase 2 clinical trial.
• The core of the dispute revolves around the definition of 'Product' and 'Royalty-Bearing Patents' in the APA, with Climb Bio asserting no such patents exist to trigger payment obligations.
• The case qualifies for assignment to the Superior Court's Complex Commercial Litigation Division because the amount in controversy exceeds $1 million.

Stakeholder Impact

• Shareholders: Potential negative impact due to legal costs, uncertainty surrounding future financial liabilities (up to $100 million), and distraction from core operations. A favorable ruling could remove a significant financial burden and positively impact valuation.
• Employees: Potential impact on morale and focus due to ongoing litigation and the financial implications it may have on the company's resources.
• Creditors: Potential impact on financial stability and creditworthiness depending on the outcome of the lawsuit and the magnitude of any required payments, which could affect the company's ability to meet future obligations.

Next Steps

• The Delaware Superior Court will intervene to resolve the dispute between Climb Bio and Alumis Inc. regarding the Asset Purchase Agreement.
• Climb Bio seeks a declaratory judgment from the court that its budoprutug candidate is not a 'Product' under the APA and that it does not owe the $3 million payment.
• Alumis Inc. expects a $3 million payment from Climb Bio by January 1, 2026, which is the subject of the current dispute.

Key Dates

Recommendation

While Climb Bio is making progress in its clinical development of budoprutug, the ongoing legal dispute with Alumis Inc. introduces significant financial uncertainty. The potential liability of a $3 million milestone payment, and potentially over $100 million in future payments, represents a material risk to the company's financial outlook. Until the legal outcome is clear, the stock carries elevated risk, making a 'hold' recommendation appropriate for investors to monitor the litigation's progress and its potential impact on the company's valuation and strategic direction.

Keywords

Climb Bio, Alumis, Acelyrin, budoprutug, Asset Purchase Agreement, APA, milestone payment, litigation, Delaware Superior Court, biotechnology, clinical trial, Phase 2, immune-mediated diseases, CD19, monoclonal antibody, patent dispute, Royalty-Bearing Patents, biopharmaceutical, legal dispute